newsfilter
← Latest News
GlobeNewswire·

Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update

Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval